Abstract
Non receptor protein tyrosine kinases are targets in the treatment of a number of diseases. This review focuses on the role of Fes tyrosine kinase and on the design of inhibitors of this protein. Fes and its homologously related protein Fer are the only two members of a distinct class of non receptor tyrosine kinases and they seem to play a role in cytoskeletal rearrangements and inside-out signalling associated with receptor-ligand, cell-matrix and cell-cell interactions. The knowledge of the three dimensional structure of this protein, in fact, has informed drug design, while at the same time it has helped to shed some light on the molecular mechanism at the basis of kinase activation and functions.
Keywords: Fes kinase, non receptor tyrosine kinase, structure based drug design, protein structure, protein crystallography
Current Medicinal Chemistry
Title: Role of the Non-Receptor Tyrosine Kinase Fes in Cancer
Volume: 18 Issue: 19
Author(s): F. Condorelli, E. Stec-Martyna, J. Zaborowska, L. Felli, I. Gnemmi, M. Ponassi and C. Rosano
Affiliation:
Keywords: Fes kinase, non receptor tyrosine kinase, structure based drug design, protein structure, protein crystallography
Abstract: Non receptor protein tyrosine kinases are targets in the treatment of a number of diseases. This review focuses on the role of Fes tyrosine kinase and on the design of inhibitors of this protein. Fes and its homologously related protein Fer are the only two members of a distinct class of non receptor tyrosine kinases and they seem to play a role in cytoskeletal rearrangements and inside-out signalling associated with receptor-ligand, cell-matrix and cell-cell interactions. The knowledge of the three dimensional structure of this protein, in fact, has informed drug design, while at the same time it has helped to shed some light on the molecular mechanism at the basis of kinase activation and functions.
Export Options
About this article
Cite this article as:
Condorelli F., Stec-Martyna E., Zaborowska J., Felli L., Gnemmi I., Ponassi M. and Rosano C., Role of the Non-Receptor Tyrosine Kinase Fes in Cancer, Current Medicinal Chemistry 2011; 18(19) . https://dx.doi.org/10.2174/092986711796150522
DOI https://dx.doi.org/10.2174/092986711796150522 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Topoisomerase II Inhibitors and Poisons, and the Influence of Cell Cycle Checkpoints
Current Medicinal Chemistry Quinone-Based Drugs: An Important Class of Molecules in Medicinal Chemistry
Medicinal Chemistry Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase
Current Drug Targets Characterisation of Small Supernumerary Marker Chromosomes (sSMC) in Human
Current Genomics Targeted Therapy for Advanced Urothelial Cancer of the Bladder: Where Do We Stand?
Anti-Cancer Agents in Medicinal Chemistry Intracellular Calcium, Endothelial Cells and Angiogenesis
Recent Patents on Anti-Cancer Drug Discovery Aurora B: A New Prognostic Marker and Therapeutic Target in Cancer
Current Medicinal Chemistry Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?
Endocrine, Metabolic & Immune Disorders - Drug Targets Large Granular Lymphocyte (LGL) Leukemia: Pathobiology, Diagnosis and Treatment
Current Cancer Therapy Reviews Perspectives in Nanomedicine-Based Research Towards Cancer Therapies
Current Nanoscience Development of Patents and Clinical Trials on Regenerative Therapy: Gene Therapy
Recent Patents on Regenerative Medicine Structural and Functional Organization of miRNAs
Current Pharmacogenomics Retinoic Acid and Iron Metabolism: A Step Towards Design of a Novel Antitubercular Drug
Current Pharmaceutical Biotechnology Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Current Drug Targets The Fate of Nanoparticles In Vivo and the Strategy of Designing Stealth Nanoparticle for Drug Delivery
Current Drug Targets Editorial: Looking Forward to Another Successful Year
Current Cancer Drug Targets Metastatic Breast Cancer, Organotropism and Therapeutics: A Review
Current Cancer Drug Targets Therapy of Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia
Current Pharmaceutical Design Blocking HIV-1 Vif Restores a Natural Mechanism of Intracellular Antiviral Defense
Current Drug Targets - Immune, Endocrine & Metabolic Disorders The PA207 Peptide Inhibitor of LIM-only Protein 2 (Lmo2) Targets Zinc Finger Domains in a Non-specific Manner
Protein & Peptide Letters